CureVac Launches Phase 2a Clinical Trial with COVID-19 Vaccine Candidate

TÜBINGEN, Germany / BOSTON, USA - September 29, 2020 -- CureVac NV (Nasdaq: CVAC), a biopharmaceutical company developing a new class of drugs based on messenger ribonucleic acid (mRNA) in clinical trials, announced today that it is the first...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials